DNA encoding a human serotonin (5-HT2) receptor and uses thereof

Abstract

The present invention provides an isolated nucleic acid molecule encoding an 5-HT 2 receptor, and an isolated protein which is a human 5-HT 2 receptor. The invention also provides vectors comprising DNA molecules encoding a human 5-HT 2 receptor, and vectors adapted for expression of the 5-HT 2 receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT 2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT 2 receptor can bind to the 5-HT 2 receptor, a method for detecting the presence of 5-HT 2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT 2 receptor. The invention herein also concerns an antibody directed to the human 5-HT 2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT 2 receptor present on the surface of a cell and having an amino acid sequence included within the amino acid sequence shown in FIG. 2.

What is claimed is:  
     
         1 . An isolated nucleic acid molecule encoding a human 5-HT 2  receptor.  
     
     
         2 . A DNA molecule of  claim 1 .  
     
     
         3 . A cDNA molecule of  claim 2  having a coding sequence substantially the same as the coding sequence shown in FIG. 2.  
     
     
         4 . A DNA molecule of  claim 2 .  
     
     
         5 . An isolated protein which is a human 5-HT 2  receptor.  
     
     
         6 . An isolated protein having substantially the same amino acid sequence as the amino acid sequence shown in FIG. 2.  
     
     
         7 . A vector comprising the DNA molecule of  claim 2 .  
     
     
         8 . A virus comprising the DNA molecule of  claim 2 .  
     
     
         9 . A bacteriophage comprising the DNA molecule of  claim 2 .  
     
     
         10 . A plasmid comprising the DNA molecule of  claim 2 .  
     
     
         11 . A vector comprising the cDNA molecule of  claim 3 .  
     
     
         12 . A virus comprising the cDNA molecule of  claim 3 .  
     
     
         13 . A bacteriophage comprising the cDNA molecule of  claim 3 .  
     
     
         14 . A plasmid comprising the cDNA molecule of  claim 3 .  
     
     
         15 . A vector comprising the DNA molecule of  claim 4 .  
     
     
         16 . A virus comprising the DNA molecule of  claim 4 .  
     
     
         17 . A bacteriophage comprising the DNA molecule of  claim 4 .  
     
     
         18 . A plasmid comprising the DNA molecule of  claim 4 .  
     
     
         19 . The plasmid of  claim 14  designated clone 6B.  
     
     
         20 . A plasmid adapted for expression in a bacterial cell which comprises the DNA molecule of  claim 2  and the regulatory elements necessary for expression of the DNA in the bacterial cell.  
     
     
         21 . A plasmid adapted for expression in a bacterial cell which comprises the cDNA molecule of  claim 3  and the regulatory elements necessary for expression of the cDNA in the bacterial cell.  
     
     
         22 . A plasmid adapted for expression in a bacterial cell which comprises the DNA molecule of  claim 4  and the regulatory elements necessary for expression of the DNA in the bacterial cell.  
     
     
         23 . A plasmid adapted for expression in a yeast cell which comprises the DNA molecule of  claim 2  and the regulatory elements necessary for expression of the DNA in the yeast cell.  
     
     
         24 . A plasmid adapted for expression in a yeast cell which comprises the cDNA molecule of  claim 3  and the regulatory elements necessary for expression of the cDNA in the yeast cell.  
     
     
         25 . A plasmid adapted for expression in a yeast cell which comprises the DNA molecule of  claim 4  and the regulatory elements necessary for expression of the DNA in the yeast cell.  
     
     
         26 . A plasmid adapted for expression in a mammalian cell which comprises the DNA molecule of  claim 2  and the regulatory elements necessary for expression of the DNA in the mammalian cell.  
     
     
         27 . A plasmid adapted for expression in a mammalian cell which comprises the cDNA molecule of  claim 3  and the regulatory elements necessary for expression of the cDNA in the mammalian cell.  
     
     
         28 . A plasmid adapted for expression in a mammalian cell which comprises the DNA molecule of  claim 4  and the regulatory elements necessary for expression of the DNA in the mammalian cell.  
     
     
         29 . The plasmid of  claim 27  designated pMO5-6B and deposited under ATCC Accession No.  
     
     
         30 . A mammalian cell comprising the DNA molecule of  claim 2 .  
     
     
         31 . A mammalian cell comprising the cDNA molecule of  claim 3 .  
     
     
         32 . A mammalian cell comprising the DNA molecule of  claim 4 .  
     
     
         33 . A mammalian cell comprising the plasmid of  claim 26 .  
     
     
         34 . A mammalian cell comprising the plasmid of  claim 27 .  
     
     
         35 . A mammalian cell comprising the plasmid of  claim 28 .  
     
     
         36 . A transfected Ltk cell comprising the plasmid of  claim 26 .  
     
     
         37 . A transfected Ltk cell comprising the plasmid of  claim 27 .  
     
     
         38 . A transfected Ltk cell comprising the plasmid of  claim 28 .  
     
     
         39 . The transfected Ltk cell of  claim 37  designated L-NGC-5HT 2  and deposited under ATCC Accession No.  
     
     
         40 . A method for determining whether a ligand which is not known to be capable of binding to the 5-HT 2  receptor can bind to the 5-HT 2  receptor which comprises contacting a mammalian cell of  claim 33  with the ligand under conditions permitting binding of ligands known to bind to the 5-HT 2  receptor, detecting the presence of any of the ligand bound to the 5-HT 2  receptor and thereby determining whether the ligand binds to the 5-HT 2  receptor.  
     
     
         41 . A method for determining whether a ligand which is not known to be capable of binding to the 5-HT 2  receptor can bind to the 5-HT 2  receptor which comprises contacting a mammalian cell of  claim 34  with the ligand under conditions permitting binding of ligands known to bind to the 5-HT 2  receptor, detecting the presence of any of the ligand bound to the 5-HT 2  receptor and thereby determining whether the ligand binds to the 5-HT 2  receptor.  
     
     
         42 . A method for determining whether a ligand which is not known to be capable of binding to the 5-HT 2  receptor can bind to the 5-HT 2  receptor which comprises contacting a mammalian cell of  claim 35  with the ligand under conditions permitting binding of ligands known to bind to the 5-HT 2  receptor, detecting the presence of any of the ligand bound to the 5-HT 2  receptor and thereby determining whether the ligand binds to the 5-HT 2  receptor.  
     
     
         43 . A method of  claim 41 , wherein the mammalian cell is Ltk − .  
     
     
         44 . A method of detecting the presence of mRNA coding for the 5-HT 2  receptor in a cell which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the cDNA molecule of  claim 3  under hybridizing conditions, detecting the presence of mRNA hybridized to the cDNA molecule, and thereby detecting the presence of mRNA encoding the 5-HT 2  receptor in the cell.  
     
     
         45 . A DNA probe useful for detecting nucleic acid encoding the 5-HT 2  receptor comprising a nucleic acid molecule of at least about 15 nucleotides having a sequence complementary to a coding sequence included within the sequence shown in FIG. 2.  
     
     
         46 . An antibody directed to the human 5-HT 2  receptor.  
     
     
         47 . A monoclonal antibody directed to an epitope of the 5-HT 2  receptor present on the surface of a cell and having an amino acid sequence substantially the same as any part of the amino acid sequence shown in FIG. 2.  
     
     
         48 . A method of detecting the presence of the 5-HT 2  receptor on the surface of a cell which comprises contacting the cell with a monoclonal antibody of  claim 47  under conditions permitting binding of the monoclonal antibody to the receptor, detecting the presence of the monoclonal antibody bound to the cell, and thereby the presence of the 5-HT 2  receptor on the surface of the cell.  
     
     
         49 . A method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT 2  receptor on the surface of a cell which comprises contacting the mammalian cell of  claim 33  with a plurality of drugs, determining those drugs which bind to the mammalian cell, and thereby identifying drugs which specifically interact with, and bind to, the 5-HT 2  receptor.  
     
     
         50 . A method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT 2  receptor on the surface of a cell which comprises contacting the mammalian cell of  claim 34  with a plurality of drugs, determining those drugs which bind to the mammalian cell, and thereby identifying drugs which specifically interact with, and bind to, the 5-HT 2  receptor.  
     
     
         51 . A method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT 2  receptor on the surface of a cell which comprises contacting the mammalian cell of  claim 35  with a plurality of drugs, determining those drugs which bind to the mammalian cell, and thereby identifying drugs which specifically interact with, and bind to, the 5-HT 2  receptor.